Type 1 DM.

Subject has severe hepatic dysfunction at Screening as determined by liver function tests:

* Bilirubin \> 2.0 mg/dL.

* ALT and/or AST \> 3 times the upper limit of normal.

* Subject has poorly controlled diabetes, based on HbA1c \> 10% at Screening.

Subject has non-diabetic renal disease.

Subject has a hypersensitivity to ACE inhibitor, CCB, torsemide or sulfonylureas.

Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)